On April 21, 2022, the 26th Tongji Forum on Pharmacology was held by the Department of Pharmacology, School of Basic Medicine, Tongji Medical College, with Professor Chao FANG presiding over the forum. This online event was supported by Queen Mary - HUST strategic partnership research funding. Prof. Mauro Perretti from Queen Mary University of London and his postdoctoral researcher Dr. Jianmin CHEN attended the forum as guest speakers and gave a lecture entitled From Resolution of Inflammation to Resolution Pharmacology.
Mauro Perretti is Professor of Immunopharmacology and Dean for Research and Research Impact of the Faculty of Medicine and Dentistry, Queen Mary University of London. Prof. Mauro Perretti received his BSc in Medicinal Chemistry and MSc in Pharmacology and Toxicology from the University of Florence in 1985 and 1989 respectively. In 1991, he joined Prof. Rod Flower at the William Harvey Research Institute and started his postdoctoral research after gaining his PhD there in 1996. Mauro gained his personal chair by Queen Mary University of London in 2001. Centre Lead of the Centre for Biochemical Pharmacology from 2001-to 2013, Mauro acted as Deputy Director of the William Harvey Research Institute from 2006 to 2013, taking on Co-Directorship in the period 2013-2016. Mauro's research career has focused on inflammation. Over the last two decades he has deciphered several mediators and pathways of resolution in the context of arthritis, sepsis and reperfusion injury, making an internationally recognized contribution to inflammation resolution research. Mauro has more than 400 publications with over 35,000 citations and an H Factor of 90.
Dr. Jianmin Chen started her postdoctoral career at William Harvey Research Institute, Queen Mary University of London, under the leadership of Prof. Mauro Perretti. Dr. Jianmin Chen gained her PhD in clinical medicine from Sichuan University in 2012 and PhD in cardiovascular pharmacology from Queen Mary University of London in 2016. Dr. Chen's research interest lies in inflammatory arthritis-related cardiomyopathy, the pharmacological effects of formyl peptide receptor 2 (FPR2) agonists in particular. Dr. Jianmin Chen has received New Investigator Award from the European Shock Society (ESS) and Career Development Award from Versus Arthritis, a nonprofit organization focused on investing in breakthrough treatments, the best information and vital support for everyone affected by arthritis.
Prof. Mauro Perretti introduced the latest research on inflammation resolution. Dr. Jianmin Chen shared their recent research on the role and molecular mechanism of formyl peptide receptor 2 (FPR2) agonists in inflammatory arthritis-related cardiomyopathy. The lecture ended up with a lively discussion between participants and two guest speakers. Teachers and students present raised questions about the establishment and application of an animal model of rheumatoid arthritis, and the potential application of FPR2 agonists to such chronic inflammatory diseases as atherosclerosis. Going forward, Prof. Chao FANG and Prof. Mauro Perretti will carry out in-depth collaborative research on the formation mechanism of inflammatory thrombosis and drug intervention strategies relying on Queen Mary - HUST strategic partnership research funding.
